Weekly Digest – April 2025 Weekly Digest – April 2025 22 Apr 2025: Synthetic Design Lab emerges with $20M to advance next-generation ADCs Synthetic Design Lab launched with $20 million in seed funding to develop next-generation antibody-drug conjugates (ADCs) using […]
Weekly Digest – April 2025 Weekly Digest – April 2025 22 Apr 2025: 1st Biotherapeutics and Ligachem Biosciences partner on ADC payloads and immuno-oncology candidates 1st Biotherapeutics and LigaChem Biosciences have formed a strategic R&D and licensing option agreement to […]
Weekly Digest – April 2025 Weekly Digest – April 2025 17 Apr 2025: Blenrep (Belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple Myeloma UK MHRA approved Blenrep (Belantamab mafodotin) in combination therapies for relapsed/refractory multiple Myeloma, marking the […]
Weekly Digest – April 2025 Weekly Digest – April 2025 17 Apr 2025: Hansoh Pharma announces NMPA has granted Breakthrough Therapy Designated drug for B7-H3-targeted antibody-drug conjugate HS-20093 for nsNSCLC Hansoh Pharma announced that its B7-H3-targeted antibody-drug conjugate HS-20093 has […]
Weekly Digest – April 2025 Weekly Digest – April 2025 14 Apr 2025: SYS6041 (Antibody-Drug Conjugate) obtains clinical trial approval in the U.S. CSPC Pharmaceutical Group received FDA approval to begin clinical trials in the U.S. for SYS6041, an antibody-drug […]
Weekly Digest – April 2025 Weekly Digest – April 2025 14 Apr 2025: Reveal Genomics and Ona Therapeutics join forces to advance next-generation cancer treatment Reveal Genomics and Ona Therapeutics have formed a strategic partnership to accelerate the clinical development […]
Weekly Digest – April 2025 Weekly Digest – April 2025 17 Apr 2025: BigHat Biosciences and Lilly collaborate to advance AI-driven antibody therapeutics BigHat Biosciences has partnered with Eli Lilly to develop next-generation antibody therapeutics using BigHat’s AI/ML-powered Milliner platform […]
Weekly Digest – April 2025 Weekly Digest – April 2025 15 Apr 2025: Lisata Therapeutics announces research license with Catalent Lisata Therapeutics has entered a research license agreement with Catalent to assess its peptide candidate, Certepetide, in combination with Catalent’s […]
Weekly Digest – April 2025 Weekly Digest – April 2025 08 Apr 2025: DATROWAY approved in the EU for patients with previously treated metastatic HR positive, HER2 negative breast cancer DATROWAY has been approved in the EU for adults with […]
Weekly Digest – April 2025 Weekly Digest – April 2025 07 Apr 2025: ALX Oncology received FDA clearance for its investigational new drug (IND) application for ALX2004, a novel antibody-drug conjugate (ADC) targeting EGFR-expressing solid tumor ALX Oncology received FDA […]
